Smoldering Multiple Myeloma — Trials

Smoldering Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

85 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 34
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 9%
Top sponsor: Dana-Farber Cancer Institute
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02603887	Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma	active not recruiting	Early Phase 1	20	M.D. Anderson Cancer CenterOTHER	1	Jul 17, 2026	clinicaltrials
NCT04370483	Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma	active not recruiting	Early Phase 1	1	City of Hope Medical CenterOTHER	1	Jan 5, 2026	clinicaltrials